copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Callio Therapeutics | Multi-payload antibody-drug conjugates Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187 0 million Series A financing round
Callio: Your AI-Powered Cold Call Assistant Callio is a virtual phone built for sales professionals It listens to your live calls and suggests what to say next — helping you stay confident, sound sharp, and close more deals
Callio Therapeutics Launches with US$187 Million Series A to . . . SEATTLE and SINGAPORE, March 3, 2025 — Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187 0 million Series A financing round
Callio Meet Callio: Your AI-powered content marketing and blog manager for startups and small business Plan your strategy, write content, and maximize your marketing impact across all channels—no expertise required!
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs Hummingbird granted Callio an exclusive license to use its “multi-payload” ADC technology in oncology In return, Hummingbird received equity in Callio and could get additional milestone payments Headquartered in Seattle and Singapore, Callio was launched by Frazier Life Sciences